Meeting
2016 ASCO Annual Meeting
A phase 1 study of the PI3K/mTOR inhibitor PQR309 evaluating safety, pharmacokinetics (PK) and pharmacodynamics (PD) in patients (pts) with advanced solid tumors.
Authors
Alex A. Adjei
Roswell Park Cancer Institute, Buffalo, NY
Alex A. Adjei , Grace K. Dy , Yujie Zhao , Wen Wee Ma , Mateusz Opyrchal , Hatoon Bakhribah , Sandra M Jacob , Corrie O'Hara , Askia Dozier , Natasa Cmiljanovic , Barbara Todaro , William E. Brady , Debora Schmitz , Sasa Dimitrijevic
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Developmental Therapeutics—Clinical Pharmacology and Experimental Therapeutics
Track
Developmental Therapeutics and Translational Research
Sub Track
Other Novel Agents
Clinical Trial Registration Number
NCT02483858
Citation
J Clin Oncol 34, 2016 (suppl; abstr 2560)
DOI
10.1200/JCO.2016.34.15_suppl.2560
Abstract #
2560
Poster Bd #
260
Abstract Disclosures
Similar Posters
Poster
2018 ASCO Annual Meeting
A phase I study of a novel IAP inhibitor APG-1387 in patients with advanced solid tumors.
First Author: Ruihua Xu
Poster
2015 ASCO Annual Meeting
A phase 1, dose-escalation, safety, pharmacokinetic, pharmacodynamic study of thioureidobutyronitrile, a novel p53 targeted therapy, in patients with advanced solid tumors.
First Author: Geoffrey Shapiro
Poster
2013 ASCO Annual Meeting
A phase I, dose-escalation, safety, pharmacokinetic, pharmacodynamic study of thioureidobutyronitrile, a novel p53 targeted therapy, in patients with advanced solid tumors.
First Author: Geoffrey Shapiro
Poster
2013 ASCO Annual Meeting
A phase I study of ridaforolimus (MK-8669) in pediatric patients with advanced solid tumors.
First Author: Andrew DJ Pearson